Company intelligence / Profile preview

EDP

Knoxville, Tennessee, United States

Ownership: Private
Employees: ~30
Development stage: Other

Overview

EDP Biotech developed and commercialized ColoPlex™, an early colorectal cancer diagnostic. It operated a CLIA-certified lab offering both B2B and direct-to-consumer multiplex diagnostics and CRO services. Following its merger with New Day Diagnostics in July 2023, its diagnostic pipeline expanded to additional point-of-care and direct-to-consumer products, including early-stage tests for various cancers and celiac disease.

Therapeutic areas: GastroenterologyOncologyInfectious Diseases
Modalities: Diagnostic testMultiplex assayIn-vitro diagnostic assay
Industry: Protein Biomarker Diagnostics

Partnerships

New Day Diagnostics

Beyond the preview

Go deeper on EDP.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EDP.

Explore the full profile